CIK 0001857044 · Non-accelerated filer<br>Smaller reporting company
Indaptus Therapeutics, Inc.
Sign in to watch- Ticker
- INDP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 863158720
- Phone
- (646) 427-2727
- Business address
- 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK, NY, 10019
- Former names
- Intec Parent Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-10 | MADDALUNA ANTHONY J Director | Grant or award · Stock Option (right to buy) | +12,500 | 12,500 | ||
| 2025-06-10 | Karah Hila Director | Grant or award · Stock Option (right to buy) | +12,500 | 12,500 | ||
| 2025-06-10 | Hayes William B Director | Grant or award · Stock Option (right to buy) | +12,500 | 12,500 | ||
| 2025-06-10 | Gilbert Mark John Director | Grant or award · Stock Option (right to buy) | +12,500 | 12,500 | ||
| 2025-04-10 | Sassi Nir Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −1,250 | $0.07 | $89 | 0 |
| 2025-04-10 | Sassi Nir Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −1,125 | $0.07 | $80 | 0 |
| 2025-04-10 | Sassi Nir Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −2,500 | $0.07 | $178 | 0 |
| 2025-04-10 | Sassi Nir Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −500 | $0.07 | $36 | 0 |
| 2025-04-10 | Sassi Nir Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −500 | $0.07 | $36 | 0 |
| 2025-04-10 | Sassi Nir Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −41 | $0.07 | $3 | 0 |
| 2025-04-10 | Sassi Nir Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −1,125 | $0.07 | $80 | 0 |
| 2025-04-10 | Pomerantz Roger Director | Returned to the company · Stock Option (right to buy) | −500 | $0.50 | $250 | 0 |
| 2025-04-10 | Pomerantz Roger Director | Returned to the company · Stock Option (right to buy) | −250 | $0.50 | $125 | 0 |
| 2025-04-10 | Pomerantz Roger Director | Returned to the company · Stock Option (right to buy) | −250 | $0.50 | $125 | 0 |
| 2025-04-10 | Meckler Jeffrey A Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −4,750 | $0.04 | $176 | 0 |
| 2025-04-10 | Meckler Jeffrey A Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −3,750 | $0.04 | $139 | 0 |
| 2025-04-10 | Meckler Jeffrey A Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −813 | $0.04 | $30 | 0 |
| 2025-04-10 | Meckler Jeffrey A Chief Executive Officer | Returned to the company · sStock Option (right to buy) | −1,500 | $0.04 | $56 | 0 |
| 2025-04-10 | Meckler Jeffrey A Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −1,563 | $0.04 | $58 | 0 |
| 2025-04-10 | Meckler Jeffrey A Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −1,250 | $0.04 | $46 | 0 |
Page 2 of 7 · 127 trades